MMJ Recs

DECEMBER 28, 2023

As the medical community delves into the therapeutic potential of cannabis, certain health conditions have emerged as primary candidates for its prescription. THC, the psychoactive component of cannabis, has analgesic properties that can help manage chronic pain conditions, such as neuropathic pain and arthritis.

Conditions 98

Conditions Chronic Pain Epilepsy Research and Development 98

Cannabis Law Report

AUGUST 21, 2019

PUBLISHER: CANNABIS LAW REPORT. Cannabis treatments are too expensive and do not come with enough test evidence to be effective, UK authorities have said. It also said the children’s experiences on medicinal cannabis in the should be taken into account as evidence of how well the drug works. AUTHOR: Mark Taylor.

Clinical Trials 81

Clinical Trials Nerve Pain Medicine Epilepsy 81

The Cannigma

MARCH 7, 2022

Yet cannabinol (CBN), the first cannabinoid ever discovered by modern scientists, is slowly making a comeback in the cannabis industry. . Of course, this plant is now known to be marijuana (or Type I cannabis), which is still commonly used for sleep and analgesia today. The best online schools for medical cannabis training.

THC 140

THC Sleep Clinical Trials Cannabinoids 140

Veriheal

APRIL 11, 2022

Cannabis, despite being widely available for medical and recreational consumers across the United States, remains one of the most understudied plants. federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Fortunately, the U.S. territories.

Pharmaceutical 104

Pharmaceutical Research and Development DEA Clinical Trials 104

Cannabis Law Report

MARCH 2, 2020

The UK government has eased import restrictions on medicinal cannabis, but has admitted it needs to do much more to improve access for patients. Licensed wholesalers will be able to import larger quantities of cannabis-based products, and hold supplies for future use by patients with prescriptions, according to a government release.

Medicine 59

Medicine Research and Development Clinical Trials Patients 59

Cannabis Law Report

NOVEMBER 24, 2019

Cannabis-based medicinal products. Severe treatment-resistant epilepsy. Severe treatment-resistant epilepsy. Do not offer CBD to manage chronic pain in adults unless as part of a clinical trial. 1.4 Severe treatment-resistant epilepsy. the person’s clinical condition is stable. Chronic pain.

Medicine 59

Medicine Chronic Pain Research and Development Treatment 59

Veriheal

AUGUST 31, 2020

Add onto that the difficulty of these unprecedented times, as a minority-owned business, we’re making it our priority to pay it forward and invest in the future leaders of cannabis who will break barriers and pave the way for innovation in this burgeoning industry. . Veriheal’s Innovation in Cannabis Scholarship 2020 Winners .

Research and Development 117

Research and Development Education Agriculture Patients 117

Cannabis Law Report

AUGUST 19, 2019

There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government.

Medicine 45

Medicine Patients Clinical Trials Access 45

Cannabis Law Report

JULY 13, 2019

report…… Proposals to name and shame businesses that fail to provide cannabis drugs for use in U.K. clinical trials have been made by Members of Parliament. It concludes that the main reason so few NHS cannabis prescriptions have been made in the U.K. CBD Testers.co THE REPORT. Read Abstract & Link at.

Research and Development 40

Research and Development Clinical Trials Epilepsy Patients 40

The Joint Blog

JANUARY 23, 2020

The study is titled “Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review.” ” “Medicinal cannabis has received increased research attention over recent years due to loosening global regulatory changes”, states the study’s abstract.

Clinical Trials 52

Clinical Trials Sleep Marijuana Cannabinoids 52

Cannabis Law Report

SEPTEMBER 24, 2019

T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. Doctors can prescribe Epidyolex – an oral solution of cannabidiol, which comes from the cannabis plant – if they think it will help sufferers. What is Epidyolex?

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

The Cannigma

AUGUST 26, 2021

Australia has a legal medical marijuana program, and while recreational cannabis remains illegal on the federal level, the enforcement of cannabis laws and the penalties handed out can differ widely from one territory to another. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

Cannabis Law Report

NOVEMBER 16, 2021

For multiple health and safety reasons, we believe orally dosed MYMD-1 is vastly superior to any of the available TNF inhibitors on the market today, one of which is the best-selling drug in the world.”. The secondary measures will be the safety, tolerability, and pharmacokinetics in this population of patients. Chapman continued.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Cannabis Law Report

OCTOBER 26, 2021

Chapman is a seasoned executive and global medical expert with extensive experience in designing and clinical trial protocols and conducting clinical trials. The Company’s second drug platform, Supera-CBD , is being developed to treat chronic pain, addiction and epilepsy.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Kind Meds (Cannabis Education Blog)

JANUARY 9, 2019

Medical marijuana laws have changed dramatically across the country in recent years, and now cannabis pharmaceuticals appear to be the next big leap forward in cannabis law reform. The Epidiolex FDA approval is big news for the medical marijuana industry and could help improve perceptions about medical cannabis all over the country.

Research and Development 97

Research and Development Treatment Pharmaceutical Conditions 97

The Cannigma

JUNE 15, 2021

Like all plants, cannabis contains a plethora of molecules, some of which have specific functions — such as determining the smell, taste and color of the plant, but also what types of effects it can have on you. This is why eating raw cannabis won’t necessarily get you high — it is full of non-decarboxylated THCA. CBD vs THC.

CBD 122

CBD Research and Development Epilepsy Extraction 122

Cannabis Law Report

FEBRUARY 15, 2019

The Singapore Online Citizen reports… Law & Home Affairs Minister K Shanmugam says that pharmaceutical companies are hiding their intentions behind a smokescreen when it comes to cannabis. He describes the trend of accepting cannabis medical use is driven by the “power of money and propaganda”. It causes serious brain damage.

Medicine 45

Medicine Pharmaceutical Law Cannabinoids 45

The Joint Blog

JANUARY 12, 2020

billion by 2023, according to the cannabis research firm Brightfield Group and noted by the AP. Passage of the 2018 Farm Bill, which eased federal legal restrictions on hemp cultivation and transport, unleashed a stampede of companies rushing products to the market in an absence of regulations ensuring safety, quality and effectiveness.

Pets 36

Pets CBD Clinical Trials Research and Development 36

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen.

CBD 98

CBD THC Conditions Medicine 98

Cannabis Law Report

JANUARY 13, 2020

Advance the medical literature regarding Epidiolex through publications in top-tier medical journals and at major scientific and medical meetings, notably the American Academy of Neurology and American Epilepsy Society meetings. Execute NHIE clinical program utilizing an intravenous formulation of cannabidiol.

Pharmaceutical 66

Pharmaceutical Clinical Trials Research and Development Programs 66

Cannabis Law Report

SEPTEMBER 28, 2021

DUBLIN–(BUSINESS WIRE)–The “Epilepsy – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering. This Epilepsy – Pipeline Insight, 2021 provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Epilepsy pipeline landscape.

Epilepsy 52

Epilepsy Clinical Trials Research and Development Pharmaceutical 52

Healer

DECEMBER 17, 2021

The safety profile of CBD has been acknowledged by major health agencies, such as the World Health Organization (WHO), showing that it’s well-tolerated by animals and humans and rarely produces any dangerous side effects. Patients using warfarin need to have their blood INR level tested after adding THC-containing cannabis to their regimen.

CBD 52

CBD THC Conditions Medicine 52

Cannabis Law Report

JUNE 1, 2021

Director of Medical Affairs and a Product Development Team lead at Greenwich Biosciences, where he played an important role in the complex, successful commercialization of the first cannabis-based product approved by the FDA to treat rare forms of epilepsy. Cautionary Note on Forward-Looking Statements.

Research and Development 66

Research and Development Treatment Pharmaceutical Patients 66

Cannabis Law Report

DECEMBER 20, 2021

(“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing product candidates for pain management, CNS disorders and anti-viral indications, signed a clinical trial agreement with Altasciences Company, Inc., For more information, please visit www.virpaxpharma.com. About Altasciences.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Data 52

Canna Law Blog

APRIL 17, 2020

Unlike endocannabinoids which are naturally occurring in mammals, phytocannabinoids are produced by the cannabis plant, as well as other plants. However, stakeholders still need to establish the safety of these products with AAFCO and the FDA. Phytocannabinoids include THC, CBD, CBN, and CBG.

Pets 59

Pets Hemp CBD Food 59

Project CBD

FEBRUARY 28, 2023

The combined total from both channels — $58,293,034 — does not include CBD sales in licensed cannabis dispensaries or CBD products, such as vapes, tinctures, gummies, and other edibles sold online. (E-commerce According to the FDA, “hemp” is defined as Cannabis sativa with a tetrahydrocannabinol (THC) concentration of 0.3%

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

OCTOBER 26, 2019

One such circumstance is a clinical trial. A clinical trial in Australia must have an Australian sponsor (whether it be an individual (e.g., Two of the avenues for supply of UTGs for clinical trials are the Clinical Trial Exemption (CTX) Scheme and the Clinical Trial Notification (CTN) Scheme.

Clinical Trials 45

Clinical Trials Medicine Research and Development Compliance 45

Alchimia

FEBRUARY 1, 2022

CBD is one of the principal cannabinoids found in cannabis and, along with THC, one of its best-known compounds. Recent scientific studies have proven that cannabidiol contains the following therapeutic properties: Anticonvulsant : especially suitable to treat Dravet syndrome, a very aggressive type of childhood epilepsy. Drowsiness.

CBD 52

CBD Epilepsy Research and Development Cannabinoids 52

Cannabis Law Report

JANUARY 26, 2022

The Innovation Passport does not reduce the burden of demonstrating that a treatment may be safe and effective, but does provide research organizers with expert advice, patient input, and collaboration throughout the clinical trial design and development process through a product-specific Target Development Profile.

Therapy 52

Therapy Clinical Trials Research and Development Treatment 52

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. Because cannabis is still a schedule 1 drug in the U.S., clinical research is extremely difficult to conduct. So far, science is telling us that yes cannabis has anti-seizure actions.

Conditions 89

Conditions Therapy Cannabinoids Epilepsy 89

The Cannigma

MARCH 12, 2021

Listen & Subscribe: Very few medical cannabis advocates are against the full legalization of the plant for all adults. In this episode of The Cannabis Enigma Podcast, host Michael Schaeffer Omer-Man interviews Dr. Fisher about the various ways medical and adult-use cannabis markets interact. Dr. Ruth Fisher. Music by Desca.

Legalization 128

Legalization Patients Education Dispensary 128

Cannabis Law Report

NOVEMBER 24, 2021

Medical publications, are, in the main fairly positive toward cannabis. Published by The Journal of Cannabis Research. Medicinal cannabis has been legalised for use for a range of specified medical conditions in Australia since 2016. At the same time, the outlook on cannabis research data is largely positive. Background.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

DECEMBER 8, 2021

Charles River Laboratories, a renowned CRO engaged by Virpax to perform Food and Drug Administration (FDA) required pre-clinical studies, has completed a single dose pharmacokinetic study of dermal administration of Epoladerm in minipigs as part of the required Investigational New Drug Application (“IND”) enabling trials.

Clinical Trials 52

Clinical Trials Chronic Pain Pharmaceutical Topical 52

Peninsula Alternative Health

MAY 15, 2019

As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. Because cannabis is still a schedule 1 drug in the U.S., clinical research is extremely difficult to conduct. So far, science is telling us that yes cannabis has anti-seizure actions.

Conditions 40

Conditions Therapy Cannabinoids Epilepsy 40

Cannabis Law Report

DECEMBER 28, 2021

We added VRP324 which is an intranasally delivered cannabidiol (‘CBD’) formulation for the management of epilepsy in adults and children. Virpax has acquired the exclusive worldwide rights from Nanomerics to use its MET platform for the nasal delivery of CBD for the management of epilepsy in children (a rare pediatric disease) and adults.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

NOVEMBER 10, 2021

as well as to support Good Laboratory Practices (GLP) toxicology, safety studies and preclinical efficacy studies. The NIH has contracted with a clinical research organization to conduct additional pre-clinical efficacy studies and procured a device to be used with the manufactured GMP drug product for preclinical and clinical studies.

Research and Development 52

Research and Development Chronic Pain Pharmaceutical Clinical Trials 52

Cannabis Law Report

JULY 15, 2022

The first Australian company to be licensed to cultivate and manufacture medicinal marijuana has praised the Federal Government’s plan to allow exports of cannabis-based medicines. Secrecy has surrounded a media visit to Queensland’s first licensed cannabis farm, which is nearing completion on the Sunshine Coast.

Medicine 52

Medicine Patients Media Supply Chain 52